A Survival Model in Locally Advanced and Metastatic Pancreatic Ductal Adenocarcinoma

被引:11
|
作者
Wang, Yi [1 ,2 ]
Xiao, Xiuying [1 ]
Wang, Tianyi [1 ]
Li, Lin [2 ]
Zhu, Yue [1 ]
Xu, Haiyan [1 ]
Chu, Yuening [2 ]
Jiao, Feng [1 ]
Cui, Jiujie [1 ]
Wang, Liwei [1 ]
机构
[1] Shanghai Jiao Tong Univ, Shanghai Canc Inst, State Key Lab Oncogenes & Related Genes, Renji Hosp,Sch Med,Dept Oncol, Shanghai 200127, Peoples R China
[2] Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Oncol,Shanghai Peoples Hosp 1, Shanghai 201620, Peoples R China
来源
JOURNAL OF CANCER | 2018年 / 9卷 / 07期
基金
中国国家自然科学基金;
关键词
Pancreatic cancer; Lactate Dehydrogenase; CA-19-9; Antigen; C-reactive protein; Albumin; Prognosis; C-REACTIVE PROTEIN; SYSTEMIC INFLAMMATORY RESPONSE; LACTATE-DEHYDROGENASE PREDICTS; CARBOHYDRATE ANTIGEN 19-9; PROGNOSTIC-FACTORS; COLORECTAL-CANCER; SERUM-ALBUMIN; GEMCITABINE; RISK; LDH;
D O I
10.7150/jca.23984
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The prognostic role of serum LDH, CA19-9, CRP and ALB in PDAC patients are controversial. In contrast to single factor, there is much less information about the prognostic value of the combination of the four factors in locally advanced and metastatic PDAC patients. It's essential to set up a survival model with the combination of tumor metabolism, tumor biomarker, systemic inflammation and nutritional status to eliminate the prognostic inaccuracy in single biomarker. 94 advanced PDAC patients who received palliative chemotherapy from 2009 to 2017 were recruited for this study. The predictive value of pretreatment serum LDH, CA19-9, CRP and ALB levels for OS were evaluated, and the same as combination of the four factors. It was confirmed that serum LDH, CA19-9, CRP and ALB levels were independent prognostic factors for OS by multivariate analyses. The results of Kaplan-Meier analyses revealed that serum LDH, CA19-9, CRP, ALB levels as well as the combination of the four factors were correlated with OS. It's concluded that the combination of the pretreatment serum LDH, CA19-9, CRP and ALB levels is a prognostic factor for advanced PDAC patients.
引用
收藏
页码:1301 / 1307
页数:7
相关论文
共 50 条
  • [21] Pancreatic ductal adenocarcinoma: metastatic disease
    A. J. Muñoz Martín
    J. Adeva
    J. Martínez-Galán
    J. J. Reina
    M. Hidalgo
    Clinical and Translational Oncology, 2017, 19 : 1423 - 1429
  • [22] Locally Advanced or Metastatic Pancreatic Adenocarcinoma: Easily Available Factors of Predictive Prolonged Survival Under Gemcitabine
    Ploquin, Anne
    Truant, Stephanie
    Piessen, Guillaume
    Vuagnat, Perrine
    Baldini, Capucine
    Cattan, Stephane
    Hebbar, Mohamed
    IN VIVO, 2017, 31 (04): : 731 - 735
  • [23] Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma
    Maggino, Laura
    Malleo, Giuseppe
    Marchegiani, Giovanni
    Viviani, Elena
    Nessi, Chiara
    Ciprani, Debora
    Esposito, Alessandro
    Landoni, Luca
    Casetti, Luca
    Tuveri, Massimiliano
    Paiella, Salvatore
    Casciani, Fabio
    Sereni, Elisabetta
    Binco, Alessandra
    Bonamini, Deborah
    Secchettin, Erica
    Auriemma, Alessandra
    Merz, Valeria
    Simionato, Francesca
    Zecchetto, Camilla
    D'Onofrio, Mirko
    Melisi, Davide
    Bassi, Claudio
    Salvia, Roberto
    JAMA SURGERY, 2019, 154 (10) : 932 - 942
  • [24] The role of systemic therapy in borderline resectable and locally advanced pancreatic ductal adenocarcinoma
    Lo, Victor C. K.
    Goodwin, Rachel A.
    Vickers, Michael M.
    JOURNAL OF CANCER METASTASIS AND TREATMENT, 2022, 8
  • [25] Surgery for locally advanced pancreatic ductal adenocarcinoma- is it only about the vessels?
    Heckler, Max
    Hackert, Thilo
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2021, 12 (05) : 2503 - 2511
  • [26] Locally advanced unresectable and metastatic pancreatic cancer predictors of survival
    Cipriano, A.
    Snores, A.
    Tavares, A.
    Iita, A. Mesc
    Sottomayor, C.
    ANNALS OF ONCOLOGY, 2019, 30
  • [27] Prognostic impact of early nutritional support in patients affected by locally advanced and metastatic pancreatic ductal adenocarcinoma undergoing chemotherapy
    Trestini, Ilaria
    Carbognin, Luisa
    Sperduti, Isabella
    Bonaiuto, Clelia
    Auriemma, Alessandra
    Melisi, Davide
    Salvatore, Lisa
    Bria, Emilio
    Tortora, Giampaolo
    EUROPEAN JOURNAL OF CLINICAL NUTRITION, 2018, 72 (05) : 772 - 779
  • [28] A phase I dose escalation study of eryaspase in combination with modified FOLFIRINOX in locally advanced and metastatic pancreatic ductal adenocarcinoma
    Yin, Chao
    Marshall, John
    Macke, Laura Ann
    He, Aiwu Ruth
    Bouker, Kerrie
    Weinberg, Benjamin Adam
    Mukherji, Reetu
    Weiner, Louis M.
    Wang, Hongkun
    Geng, Xue
    Hoke, Frank
    Youssoufian, Hagop
    El-Hariry, Iman
    Noel, Marcus Smith
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [29] Prognostic impact of early nutritional support in patients affected by locally advanced and metastatic pancreatic ductal adenocarcinoma undergoing chemotherapy
    Ilaria Trestini
    Luisa Carbognin
    Isabella Sperduti
    Clelia Bonaiuto
    Alessandra Auriemma
    Davide Melisi
    Lisa Salvatore
    Emilio Bria
    Giampaolo Tortora
    European Journal of Clinical Nutrition, 2018, 72 : 772 - 779
  • [30] Clinical and molecular profiling of locally advanced compared with metastatic pancreatic adenocarcinoma
    Picardo, Sarah Louise
    O'Kane, Grainne M.
    Fischer, Sandra
    Zhang, Amy
    Denroche, Robert Edward
    Jang, Gun Ho
    Dodd, Anna
    Grant, Robert C.
    Grunwald, Barbara
    Moura, Shari
    Elimova, Elena
    Prince, Rebecca M.
    Zogopoulos, George
    Notta, Faiyaz
    Wilson, Julie
    Gallinger, Steven
    Knox, Jennifer J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)